Diabetes Metab J.  2025 Mar;49(2):169-171. 10.4093/dmj.2025.0047.

Glucagon-Like Peptide-1 Receptor Agonists: What’s the Optimizing Policies for Obesity-Related Metabolic Diseases?

• Park TS

• KMID: 2565341
• DOI: http://doi.org/10.4093/dmj.2025.0047

Reference

1. Park SE, Ko SH, Kim JY, Kim K, Moon JH, Kim NH, et al. Diabetes fact sheets in Korea 2024. Diabetes Metab J. 2025; 49:24–33.

2. GOV. UK. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse. Available from: https://www.gov.uk/drug-safety-update/glp-1-receptoragonists-reminder-of-the-potential-side-effects-and-to-beaware-of-the-potential-for-misuse (cited 2025 Feb 22).

3. Korea Biomedical Review. Concerns rise over misuse of obesity drug Wegovy via telemedicine platforms. Available from: https://www.koreabiomed.com/news/articleView.html?idxno=25454 (cited 2025 Feb 22).

4. Courcoulas AP, Patti ME, Hu B, Arterburn DE, Simonson DC, Gourash WF, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024; 331:654–64.

5. Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024; Feb. 1. [Epub]. https://doi.org/10.1038/s41366-024-01473-y.